TELA Bio Past Earnings Performance
Past criteria checks 0/6
TELA Bio's earnings have been declining at an average annual rate of -10.8%, while the Medical Equipment industry saw earnings growing at 8.7% annually. Revenues have been growing at an average rate of 34.1% per year.
Key information
-10.8%
Earnings growth rate
83.5%
EPS growth rate
Medical Equipment Industry Growth | 8.9% |
Revenue growth rate | 34.1% |
Return on equity | -280.2% |
Net Margin | -63.8% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Shareholders May Be More Conservative With TELA Bio, Inc.'s (NASDAQ:TELA) CEO Compensation For Now
May 29TELA Bio, Inc. (NASDAQ:TELA) Soars 31% But It's A Story Of Risk Vs Reward
May 23Earnings Update: TELA Bio, Inc. (NASDAQ:TELA) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts
Mar 24Many Still Looking Away From TELA Bio, Inc. (NASDAQ:TELA)
Mar 08TELA Bio (NASDAQ:TELA) Has Debt But No Earnings; Should You Worry?
Oct 07Getting In Cheap On TELA Bio, Inc. (NASDAQ:TELA) Might Be Difficult
Jul 31TELA Bio: Tailwinds In Hernia Repair Market And Promising Clinical Data To Drive Accelerating Adoption
Oct 02Tela Bio prices $32M common stock offering
Aug 16Is TELA Bio (NASDAQ:TELA) Using Debt Sensibly?
May 12TELA Bio - Follow Up With Management
Jan 14Our First Look At TELA Bio
Nov 04TELA Bio Plugging Away
Oct 25TELA Bio (TELA) Investor Presentation - Slideshow
May 26Bearish: Analysts Just Cut Their TELA Bio, Inc. (NASDAQ:TELA) Revenue and EPS estimates
Mar 30Health Check: How Prudently Does TELA Bio (NASDAQ:TELA) Use Debt?
Feb 12TELA Bio guides Q4 and FY20 revenue below consensus
Jan 14TELA Bio EPS misses by $0.09, beats on revenue
Nov 11Revenue & Expenses Breakdown
How TELA Bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 63 | -40 | 79 | 10 |
31 Dec 23 | 58 | -47 | 75 | 10 |
30 Sep 23 | 53 | -44 | 68 | 10 |
30 Jun 23 | 49 | -44 | 65 | 9 |
31 Mar 23 | 45 | -45 | 61 | 9 |
31 Dec 22 | 41 | -44 | 57 | 9 |
30 Sep 22 | 38 | -43 | 54 | 8 |
30 Jun 22 | 35 | -40 | 50 | 7 |
31 Mar 22 | 32 | -36 | 45 | 7 |
31 Dec 21 | 29 | -33 | 42 | 7 |
30 Sep 21 | 27 | -32 | 39 | 6 |
30 Jun 21 | 24 | -32 | 38 | 6 |
31 Mar 21 | 20 | -30 | 34 | 5 |
31 Dec 20 | 18 | -29 | 32 | 4 |
30 Sep 20 | 17 | -28 | 31 | 4 |
30 Jun 20 | 16 | -27 | 28 | 3 |
31 Mar 20 | 16 | -29 | 27 | 3 |
31 Dec 19 | 15 | -30 | 24 | 4 |
30 Sep 19 | 13 | -32 | 22 | 4 |
30 Jun 19 | 11 | -30 | 21 | 5 |
31 Mar 19 | 10 | -28 | 20 | 5 |
31 Dec 18 | 8 | -30 | 19 | 4 |
31 Dec 17 | 4 | -27 | 14 | 6 |
Quality Earnings: TELA is currently unprofitable.
Growing Profit Margin: TELA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TELA is unprofitable, and losses have increased over the past 5 years at a rate of 10.8% per year.
Accelerating Growth: Unable to compare TELA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TELA is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (2.4%).
Return on Equity
High ROE: TELA has a negative Return on Equity (-280.16%), as it is currently unprofitable.